肾损伤分子-1与肾脏疾病的研究进展

摘要
图/表
参考文献(36)
相关文章 (15)

全文: PDF (658 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要近年来肾脏疾病的患病率逐年增加，对肾损伤的早发现和早干预是避免肾功能进一步恶化的关键，因此寻找一种可以早期反应肾脏损伤的生物标志物尤为重要。肾损伤分子-1（KIM-1）是一种Ⅰ型跨膜糖蛋白，在肾脏损伤时表达迅速增加，其水平随着肾脏损伤程度增加而增，并且KIM-1可能通过不同的分子位点在肾脏修复和损伤过程中发挥着作用。尿液及血液KIM-1与各种原因导致的急性肾损伤、慢性肾脏病、IgA肾病、过敏性紫癜肾炎、肾脏肿瘤等疾病有关，KIM-1不仅是肾脏损伤的早期生物标志物，而且在预测肾脏预后方面具有潜在的作用。本文就KIM-1与肾脏疾病的研究进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵宁朱国贞

关键词 ：肾损伤分子-1, 肾脏疾病, 生物标志物, 早期诊断

Abstract：In recent years, the prevalence of renal diseases has increased year by year. Early detection and early intervention of renal injury is the key to avoid further deterioration of renal function. Therefore, it is particularly important to find a biomarker that can early reflect renal injury. Kidney injury molecule-1 (KIM-1) is a type Ⅰ membrane protein, and expression increases rapidly during kidney injury, and its level increases with the degree of kidney injury. KIM-1 may play a role in the process of renal repair and injury through different molecular sites. KIM-1 in urine and blood are associated with various causes of acute renal injury, chronic renal disease, IgA nephropathy, henoch-schonlein purpura kidney and renal tumor. KIM-1 is not only an early biomarker of renal injury, but also has a potential role in predicting renal prognosis. This article reviews the research progress of KIM-1 and renal diseases.

Key words： Kideny injury molecule-1 Renal disease Biomarker Early diagnosis

基金资助:山西省国际科技合作项目（2015081036）。

通讯作者: 朱国贞（1974.5-），女，博士，主任医师；研究方向：肾小球疾病的临床与基础研究。

作者简介: 赵宁（1993.9-），男，山西医科大学第二医院2017级内科学专业在读硕士研究生；研究方向：肾小球疾病的临床与基础研究。

引用本文:

赵宁朱国贞. 肾损伤分子-1与肾脏疾病的研究进展[J]. 中国医药导报, 2020, 17(33): 53-56.
ZHAO Ning ZHU Guozhen. Research progress of renal injury molecule-1 and renal diseases. 中国医药导报, 2020, 17(33): 53-56.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I33/53

[1] Moresco RN，Bochi GV，Stein CS，et al. Urinary kidney injury molecule-1 in renal disease [J]. Clin Chim Acta，2018，487：15-21.
[2] Song J，Yu J，Prayogo GW，et al. Understanding kidney injury molecule 1：a novel immune factor in kidney pathophysiology [J]. Am J Transl Res，2019，11（3）：1219-1229.
[3] Pennemans V，Rigo JM，Faes C，et al. Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population：are age and gender an issue? [J]. Clin Chem Lab，2013，51（9）：1795-1802.
[4] Lim AI，Tang SC，Lai KN，et al. Kidney injury molecule-1：more than just an injury marker of tubular epithelial cells? [J]. J Cell Physiol，2013，228（5）：917-924.
[5] Medi■ B，Rovcanin B，Vujovic KS，et al. Evaluation of novel biomarkers of acute kidney injury：the possibilities and limitations [J]. Curr Med Chem，2016，23（19）：1981-1997.
[6] Ismail OZ，Zhang X，Wei J，et al. Kidney injury molecule-1 protects against Galpha12 activation and tissue damage in renal ischemia-reperfusion injury [J]. Am J Pathol，2015，185（5）：1207-1215.
[7] Waanders F，van Timmeren MM，Stegeman CA，et al. Kidney injury molecule-1 in renal disease [J]. J Pathol，2010，220（1）：7-16.
[8] Yu W，Beaudry S，Negoro H，et al. H2O2 activates G protein，alpha 12 to disrupt the junctional complex and enhance ischemia reperfusion injury [J]. Proc Natl Acad Sci U S A，2012，109（17）：6680-6685.
[9] Ismail OZ，Zhang X，Bonventre JV，et al. G protein α12（Gα12）is a negative regulator of kidney injury molecule-1-mediated efffferocytosis [J]. Am J Phys Renal Physiol，2016，310（7）：F607-F620.
[10] Humphreys BD，Xu F，Sabbisetti V，et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis [J]. J Clin Invest，2013，123（9）：4023-4035.
[11] Ahmed SA，Hamed MA. Kidney injury molecule-1 as a predicting factor for inflamed kidney，diabetic and diabetic nephropathy Egyptian patients [J]. J Diabetes Metab Disord，2015，14：6.
[12] Tu Y，Wang H，Sun R，et al. Urinary netrin-1 and KIM-1 as early biomarkers for septic acute kidney injury [J]. Ren Fail，2014，36（10）：1559-1563.
[13] Petrovic S，Bogavac-Stanojevic N，Peco-Antic A，et al. Clinical application neutrophil gelatinase-associated lipocalin and kidney injury moleucle-1 as indicators of inflammation persistence and acute kidney injury in children with urinary tract infection [J]. Biomed Res Int，2013，2013：947157.
[14] Westhoff JH，Seibert FS，Waldherr S，et al. Urinary calprotectin，kidney injury molecule-1，and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury [J]. Eur J Pediatr，2017，176（6）：745-755.
[15] Xue W，Xie Y，Wang Q，et al. Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidneyinjury in an obstructive nephropathy patient [J]. Nephrology（Carlton），2014，19（4）：186-194.
[16] Shinke H，Masuda S，Togashi Y，et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients [J]. Cancer Chemother Pharmacol，2015，76（5）：989-996.
[17] Li W，Yu Y，He H，et al. Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention [J]. Biomed Rep，2015，3（4）：509-512.
[18] GBD Chronic Kidney Disease Collaboration. Global，regional，and national burden of chronic kidney disease，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2020，395（10225）：709-733.
[19] Lobato GR，Lobato MR，Thomé FS，et al. Performance of urinary kidney injury molecule-1，neutrophil gelatinase-associated lipocalin，and N-acetylbeta-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes [J]. Braz J Med Biol Res，2017，50（5）：e6106.
[20] Rotbain Curovic V，Hansen TW，Eickhoff MK，et al. Urinary tubular biomarkers as predictors of kidney function decline，cardiovascular events and mortality in microalbuminuric type 2 diabetic patients [J]. Acta Diabetol，2018，55（11）：1143-1150.
[21] Waikar SS，Sabbisetti V，?魧rnl?觟v J，et al. Relationship of proximal tubular injury to chronic kidney disease as assessed byurinary kidney injury molecule-1 in fifive cohort studies [J]. Nephrol Dial Transplant，2016，31（9）：1460-1470.
[22] Moresco RN，De Carvalho JAM. Applying proteomics to diagnosis of diabetic kidney disease [J]. Expert Rev Proteomics，2017，14（10）：841-843.
[23] De Carvalho JA，Tatsch E，Hausen BS，et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes [J]. Clin Biochem，2016，49（3）：232-236.
[24] Satirapoj B，Pooluea P，Nata N，et al. Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy：A prospective cohort study [J]. J Diabetes Complications，2019，33（9）：675-681.
[25] Siddiqui K，Joy SS，Al-Rubeaan K，et al. Association of urinary monocyte chemoattractant protein-1 （MCP-1） and kidney injury molecule-1 （KIM-1） with risk factors of diabetic kidney disease in type 2 diabetes patients [J]. Int Urol Nephrol，2019，51（8）：1379-1386.
[26] Gou R，Chen J，Sheng S，et al. KIM-1 mediates high glucose-induced autophagy and apoptosis in renal tubular epithelial cells [J]. Cell Physiol Biochem，2016，38（6）：2479-2488.
[27] Zhao X，Chen X，Zhang Y，et al. Kidney Injury Molecule-1 Is Upregulated in Renal Lipotoxicity and Mediates Palmitate-Induced Tubular Cell Injury and Inflammatory Response [J]. Int J Mol Sci，2019，20（14）：3406.
[28] 曹冰，刘颖，张静，等.尿肾损伤分子-1在IgA肾病临床评估中的意义[J].中国医学前沿杂志：电子版，2019， 11（8）：88-93.
[29] Zhang Y，Li A，Wen J，et al. Kidney Injury Molecule-1 Level is Associated with the Severity of Renal Interstitial Injury and Prognosis in Adult Henoch-Sch?觟nlein Purpura Nephritis [J]. Arch Med Res，2017，48（5）：449-458.
[30] Zhang PL ，Mashni JW，Sabbisetti VS，et al. Urine kidney injury molecule-1：a potential non-invasive biomarker for patients with renal cell carcinoma [J]. Int Urol Nephrol，2014，46（2）：379-388.
[31] Zhang KJ，Wilson GD，Kara S，et al. Diagnostic role of kidney injury molecule-1 in renal cell carcinoma [J]. Int Urol Nephrol，2019，51（11）：1893-1902.
[32] Cuadros T，Trilla E，Sarró E，et al. HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome [J]. Cancer Res，2014，74（5）：1416-1428.
[33] Xu J，Sun L，Sun W，et al. Targeted Silencing of Kim-1 Inhibits the Growth of Clear Cell Renal Cell Carcinoma Cell Line 786-0 In Vitro and In Vivo [J]. Oncol Res，2018，26（7）：997-1003.
[34] Thomas LJ，Vitale L，O’Neill T，et al. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian，Lung，and Renal Cell Carcinoma Expressing TIM-1 [J]. Mol Cancer Ther，2016，15（12）：2946-2954.
[35] Scelo G，Muller DC，Riboli E，et al. KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer：A Prospective Nested Case-Control Study [J]. Clin Cancer Res，2018，24（22）：5594-5601.
[36] Kushlinskii NE，Gershtein ES，Naberezhnov DS，et al. Kidney Injury Molecule-1（KIM-1）in Blood Plasma of Patients with Clear-Cell Carcinoma [J]. Bull Exp Biol Med，2019，167（3）：388-392.